Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07163273 · ClinicalTrials.gov registry record · Phase 2
Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma
A Phase 2 study of Pancreatic Ductal Adenocarcinoma, sponsored by Northwell Health.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 7
- Study locations
NCT07163273 is a Phase 2 study of Pancreatic Ductal Adenocarcinoma that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 41 participants, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 1 state.
The verdict
NCT07163273, a Phase 2 study of Pancreatic Ductal Adenocarcinoma, is actively recruiting participants, sponsored by Northwell Health.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 7
- Study locations
Study Summary
A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX and GnP has better efficacy compared to historical observation.
Conditions Studied
Interventions
- DRUG NALIRIFOX
- DRUG Gemcitabine plus nab-Paclitaxel (GnP)
Study Locations (7)
New York
- Imbert Cancer Center - Bay Shore
- Northern Westchester Cancer Center - Mount Kisco
- Long Island Jewish Medical Center - New Hyde Park
- Zuckerberg Cancer Center - New Hyde Park
- Manhattan Eye, Ear and Throat Hospital - New York
- NHPP Medical Oncology at Rego Park - Rego Park
- Phelps Cancer Center - Sleepy Hollow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2027-06-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07163273
The ClinicalTrials.gov registry entry for NCT07163273 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 600-participant average among 84 other Pancreatic Ductal Adenocarcinoma trials with a reported enrollment target (93% lower). The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Ductal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which NALIRIFOX is the first listed.
NCT07163273 reports 7 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07163273 about?
NCT07163273 is a clinical study titled "Monthly Alternating NALIRIFOX and GnP in the First-Line Setting for Metastatic Pancreatic Ductal Adenocarcinoma". A prospective, interventional, single-center, single-arm, open-label, phase II study for patients with metastatic pancreatic cancer. The intervention consists of monthly alternating standard chemotherapy regimens-NALIRIFOX and GnP. The hypothesis is that induction therapy with alternating NALIRIFOX ...
What is the current status of trial NCT07163273?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2025-06-20. Estimated completion is 2027-06-20.
What conditions does trial NCT07163273 study?
This clinical trial studies the following conditions: Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT07163273?
The interventions under investigation include: NALIRIFOX (DRUG), Gemcitabine plus nab-Paclitaxel (GnP) (DRUG).
Who is sponsoring clinical trial NCT07163273?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07163273 being conducted?
This trial has 7 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Ductal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Maintenance Combinatorial Myeloid Immunotherapy for Unresectable Pancreatic Cancer
RECRUITING · Phase 2
-
A Study of NALIRIFOX in Combination With Radiation Therapy in People With Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 2
-
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
RECRUITING · Phase 2
-
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
RECRUITING · Phase 2
-
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.